National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved..
A consensus meeting of national experts from all major national hepatobiliary centres in the country was held on May 26, 2023, at the Pakistan Kidney and Liver Institute & Research Centre (PKLI & RC) after initial consultations with the experts. The Pakistan Society for the Study of Liver Diseases (PSSLD) and PKLI & RC jointly organised this meeting. This effort was based on a comprehensive literature review to establish national practice guidelines for hilar cholangiocarcinoma (hCCA). The consensus was that hCCA is a complex disease and requires a multidisciplinary team approach to best manage these patients. This coordinated effort can minimise delays and give patients a chance for curative treatment and effective palliation. The diagnostic and staging workup includes high-quality computed tomography, magnetic resonance imaging, and magnetic resonance cholangiopancreatography. Brush cytology or biopsy utilizing endoscopic retrograde cholangiopancreatography is a mainstay for diagnosis. However, histopathologic confirmation is not always required before resection. Endoscopic ultrasound with fine needle aspiration of regional lymph nodes and positron emission tomography scan are valuable adjuncts for staging. The only curative treatment is the surgical resection of the biliary tree based on the Bismuth-Corlette classification. Selected patients with unresectable hCCA can be considered for liver transplantation. Adjuvant chemotherapy should be offered to patients with a high risk of recurrence. The use of preoperative biliary drainage and the need for portal vein embolisation should be based on local multidisciplinary discussions. Patients with acute cholangitis can be drained with endoscopic or percutaneous biliary drainage. Palliative chemotherapy with cisplatin and gemcitabine has shown improved survival in patients with irresectable and recurrent hCCA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
World journal of gastroenterology - 30(2024), 9 vom: 07. März, Seite 1018-1042 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3748/wjg.v30.i9.1018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370665996 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370665996 | ||
| 003 | DE-627 | ||
| 005 | 20240408233048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3748/wjg.v30.i9.1018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM370665996 | ||
| 035 | |a (NLM)38577184 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dar, Faisal Saud |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a A consensus meeting of national experts from all major national hepatobiliary centres in the country was held on May 26, 2023, at the Pakistan Kidney and Liver Institute & Research Centre (PKLI & RC) after initial consultations with the experts. The Pakistan Society for the Study of Liver Diseases (PSSLD) and PKLI & RC jointly organised this meeting. This effort was based on a comprehensive literature review to establish national practice guidelines for hilar cholangiocarcinoma (hCCA). The consensus was that hCCA is a complex disease and requires a multidisciplinary team approach to best manage these patients. This coordinated effort can minimise delays and give patients a chance for curative treatment and effective palliation. The diagnostic and staging workup includes high-quality computed tomography, magnetic resonance imaging, and magnetic resonance cholangiopancreatography. Brush cytology or biopsy utilizing endoscopic retrograde cholangiopancreatography is a mainstay for diagnosis. However, histopathologic confirmation is not always required before resection. Endoscopic ultrasound with fine needle aspiration of regional lymph nodes and positron emission tomography scan are valuable adjuncts for staging. The only curative treatment is the surgical resection of the biliary tree based on the Bismuth-Corlette classification. Selected patients with unresectable hCCA can be considered for liver transplantation. Adjuvant chemotherapy should be offered to patients with a high risk of recurrence. The use of preoperative biliary drainage and the need for portal vein embolisation should be based on local multidisciplinary discussions. Patients with acute cholangitis can be drained with endoscopic or percutaneous biliary drainage. Palliative chemotherapy with cisplatin and gemcitabine has shown improved survival in patients with irresectable and recurrent hCCA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Bismuth-Corlette classification | |
| 650 | 4 | |a Hepatectomy | |
| 650 | 4 | |a Hilar cholangiocarcinoma | |
| 650 | 4 | |a Memorial Sloan Kettering Cancer Centre Staging | |
| 650 | 4 | |a Portal vein embolisation | |
| 650 | 4 | |a Preoperative biliary drainage | |
| 650 | 4 | |a Surgical resection | |
| 700 | 1 | |a Abbas, Zaigham |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Irfan |e verfasserin |4 aut | |
| 700 | 1 | |a Atique, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Aujla, Usman Iqbal |e verfasserin |4 aut | |
| 700 | 1 | |a Azeemuddin, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Aziz, Zeba |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatti, Abu Bakar Hafeez |e verfasserin |4 aut | |
| 700 | 1 | |a Bangash, Tariq Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Butt, Amna Subhan |e verfasserin |4 aut | |
| 700 | 1 | |a Butt, Osama Tariq |e verfasserin |4 aut | |
| 700 | 1 | |a Dogar, Abdul Wahab |e verfasserin |4 aut | |
| 700 | 1 | |a Farooqi, Javed Iqbal |e verfasserin |4 aut | |
| 700 | 1 | |a Hanif, Faisal |e verfasserin |4 aut | |
| 700 | 1 | |a Haider, Jahanzaib |e verfasserin |4 aut | |
| 700 | 1 | |a Haider, Siraj |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Syed Mujahid |e verfasserin |4 aut | |
| 700 | 1 | |a Jabbar, Adnan Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Aman Nawaz |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Muhammad Shoaib |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Muhammad Yasir |e verfasserin |4 aut | |
| 700 | 1 | |a Latif, Amer |e verfasserin |4 aut | |
| 700 | 1 | |a Luck, Nasir Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Malik, Ahmad Karim |e verfasserin |4 aut | |
| 700 | 1 | |a Rashid, Kamran |e verfasserin |4 aut | |
| 700 | 1 | |a Rashid, Sohail |e verfasserin |4 aut | |
| 700 | 1 | |a Salih, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Saeed, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Salamat, Amjad |e verfasserin |4 aut | |
| 700 | 1 | |a Tayyab, Ghias-Un-Nabi |e verfasserin |4 aut | |
| 700 | 1 | |a Yusuf, Aasim |e verfasserin |4 aut | |
| 700 | 1 | |a Zia, Haseeb Haider |e verfasserin |4 aut | |
| 700 | 1 | |a Naveed, Ammara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of gastroenterology |d 1997 |g 30(2024), 9 vom: 07. März, Seite 1018-1042 |w (DE-627)NLM117065250 |x 2219-2840 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:9 |g day:07 |g month:03 |g pages:1018-1042 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3748/wjg.v30.i9.1018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 9 |b 07 |c 03 |h 1018-1042 | ||